Rationalisation of Polypharmacy in the Elderly by the RASP Instrument (Rationalisation of Home Medication by an Adjusted STOPP-list in Older Patients): a Prospective, Clinical Trial.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Healthy
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 172
- Locations
- 1
- Primary Endpoint
- Number of actually stopped or adjusted drugs
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The aim of this study is to determine whether a clinical pharmacist using the RASP list (RASP = Rationalisation of home medication by an adjusted STOPP-list in older patients; STOPP = Screening Tool of Older Persons' potentially inappropriate Prescriptions) can optimise the drug use in elderly inpatients.
Detailed Description
Older persons take on average multiple drugs. As people age, there is an apparent increase in pharmacodynamic sensitivity to different making the patient more prone to experience side effects. Alterations in body composition and concomitant changes in pharmacokinetic parameters can also result in a higher risk for adverse drug events. All these factors make the older person, notwithstanding the heterogeneity of this population, more vulnerable for the negative consequences of polypharmacy. Polypharmacy is a cause of negative clinical outcomes but it still remains unclear which intervention or set of interventions should be used to optimize the prescription of pharmacotherapy in the elderly patient. Therefore, the investigators developed the RASP (RASP = Rationalisation of home medication by an adjusted STOPP-list in older patients; STOPP = Screening Tool of Older Persons' potentially inappropriate Prescriptions), a list as tool to reduce polypharmacy adapted to Belgian national prescribing tendencies within geriatric wards. Content and reliability of the RASP have been validated and the investigators aim to further study the impact of the systematic implementation of this RASP on geriatric wards in a prospective cluster randomized controlled trial.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent by the patient or a caregiver if the patient is incompetent to sign
- •Consecutive inclusion of all newly admitted patients to the wards coming from home or the emergency room department
Exclusion Criteria
- •Patients not admitted to the hospital from home or a nursing home
- •Patients unable to communicate in Dutch
- •Patients admitted for palliative care
- •Patients who do not take any drugs at admission
Outcomes
Primary Outcomes
Number of actually stopped or adjusted drugs
Time Frame: Patients will be followed for the duration of hospital stay, an expected average of 14 days.
At hospital discharge the number of stopped or adjusted drugs will be determined. This variable will be compared between the two arms.
Secondary Outcomes
- Length of stay(Determined at discharge, on average after 14 days)
- Actual drug use(Measured on 30 and 90 days post-discharge.)
- Number of falls(Measured during hospitalisation, an expected average of 14 days and within 90 days after discharge)
- Incidence of delirium(Patients will be followed for the duration of hospital stay, an expected average of 14 days)
- Number and category of drugs adjusted on recommendations of the clinical pharmacist independent of RASP(Patients will be followed for the duration of hospital stay, an expected average of 14 days.)
- Mortality(Measured during hospitalisation, an expected average of 14 days and within 90 days after discharge.)
- Number of potentially inappropriate drug prescriptions as defined by the RASP.(Patients will be followed for the duration of hospital stay, an expected average of 14 days.)
- Number of falls post-discharge(Within 90 days post-discharge)
- Quality of Life (EQ-5D-3L)(Patients will be followed for the duration of hospital stay, an expected average of 14 days.)
- Rehospitalisation(Within 90 days post-discharge.)